MedTrace Logo

Expanded Access Protocol for Patients With Eosinophilic Esophagitis

NCT05095116 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-10-03

No results posted yet for this study

Summary

This expanded access program is an open-label, single-arm design where consenting patients may participate up until APT-1011 is commercially available in the relevant regions or the protocol is terminated by the Sponsor.

Conditions

  • Eosinophilic Esophagitis

Interventions

DRUG

APT-1011 3 mg HS

APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.

Sponsors & Collaborators

  • Ellodi Pharmaceuticals, LP

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05095116 on ClinicalTrials.gov